Tax inversions are one of the hottest trends in biopharma. But with lawmakers unable so far to reach a deal on new legislation, the Obama administration is signaling that it wants to put a stop to it--now. And it's looking for a way to go it alone, leaving lawmakers on the sidelines.
Shedding noncore assets is the trend du jour in Big Pharma, and now another company may be jumping on the bandwagon. Belgium's UCB is reportedly looking into a sale of Kremers Urban Pharmaceuticals, its Princeton, NJ-based generics unit.
Bill Ackman hasn't rounded up enough support to call the special meeting of Allergan shareholders that's crucial to Valeant's buyout bid. But now, he's got a proxy advisory firm to back his cause.
Minnesota's MGC Diagnostics has completed its acquisition of a promising Belgian competitor, putting its plan for global expansion in place less than a month after the M&A deal was first announced.
Roche's European-based R&D arm pRED has closed a deal to buy Denmark's Santaris Pharma, paying $250 million upfront with another $200 million up for grabs in potential milestones if the research pays off. The deal marks a big increase in Roche's bet on RNA-targeting drugs, a research sector it exited with great fanfare several years ago as experts debated the potential for the field.
Biotech startup Enumeral Biomedical has pulled off a deal that gives it $21.5 million in financing and access to public markets, paving the way for early-stage work on some cancer immunotherapies.
When Genstar Capital acquired orthopedic implant company Tecomet in December, the private equity firm aimed to build up the company's growth both organically and through acquisitions. It's making good on the latter strategy with the newly announced purchase of the equipment business of Symmetry Medical for $450 million.
Venture capital company Boston Millennia helped close out St. Jude Medical's acquisition of CardioMEMS, a major device aquisition move to join several other important deals the VC finalized this year.
Valeant and Bill Ackman's $54 billion bid for Allergan is definitely a bit unconventional. But is it insider trading? Allergan thinks so--and it's suing to prove it, a move that could hurt Valeant's chances to seal the deal.
Smith & Nephew is targeting a serious margin ramp-up and tax rate reductions within the next few years. Maintaining its aggressive acquisition strategy is an obvious means to work toward both those goals.